Harbour BioMed
http://www.harbourbiomed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Harbour BioMed
Taking On Vyvgart In Myasthenia Gravis
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
Chinese-Language Podcast: AZ收购亘喜,MNC本土重磅交易,2024展望
One week into 2024 and there have already been multiple deals between Chinese innovative drug developers and multinational partners, along with the significant acquisition of GracellBio by AstraZeneca. In this Chinese-language podcast, Brian Yang and Dexter Yan invite a guest speaker to discuss the reasons behind the particularly active China biotech deal-making scene.
Roche Signs Up Medilink As China Biotech ADC Deal Spree Continues
The Swiss drug maker teams up with Chinese biotech Medilink to gain access to a preclinical c-Met-targeting antibody-drug conjugate and potential competitor to two frontrunners from AbbVie.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Harbour Antibodies BV, Hbm Holdings Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice